CIBMTR.org
Forms Instruction Manual
Table of Contents
CIBMTR.org
Forms Instruction Manual
Getting Started
Manual Reference Diagram
Providing Feedback
Getting Started
2020 Manual Updates
2019 Manual Updates
2018 Manual Updates
2017 Manual Updates
2016 Manual Updates
2015 Manual Updates
General Instructions
Introduction
Key Fields & Signature Lines
General Guidelines for Completing Forms
Recipient Assignment, Indication, and Information Manuals
2804: CIBMTR Research ID Assignment Form
Q1-13: Demographics
Q14-18: Recipient Identifiers
Q19-22: Outcomes Registry Reporting
2814: Indication for CRID Assignment
Q1: Indication
Q2-5: Hematopoietic Cellular Transplant (HCT)
Q6: Cellular Therapy
Q7: Marrow Toxic Injury
Q8-10: Non-Cellular Therapy
2820: Recipient Contact Information
Q1-5: Indication
Q6–21: Recipient Contact Information
Q22–38: Parent / Legal Guardian Contact Information
Q39–58: Alternate Contact Information
Transplant Essential Data (TED) Manuals
2400: Pre-TED
Q1-23: Recipient Information
Q24-43: Hematopoietic Cellular Transplant (HCT) and Cellular Therapy
Q44-82: Donor Information
Q83-86: Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning)
Q87-115: Comorbid Conditions
Q116-130: Pre-HCT Preparative Regimen (Conditioning)
Q131-139: Additional Drugs Given in the Peri-Transplant Period
Q140-142: GVHD Prophylaxis
Q143-145: Post-HCT Disease Therapy Planned as of Day 0
Q146: Prior Exposure: Potential Study Eligibility
2402: Disease Classification
Q1-2: Primary Disease for HCT / Cellular Therapy
Q3-95: Acute Myelogenous Leukemia
Q96-163: Acute Lymphoblastic Leukemia
Q164-167: Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms
Q168-178: Chronic Myelogenous Leukemia
Q179-258: Myelodysplastic Diseases
Q259-371: Myeoloproliferative Diseases
Q372-378: Other Leukemia
Q379-396: Hodgkin and Non-Hodgkin Lymphoma
Q397-443: Multiple Myeloma / Plasma Cell Disorder
Q444-445: Solid Tumors
Q446-448: Severe Aplastic Anemia
Q449-450: Inherited Bone Marrow Failure Syndromes
Q451-487: Hemoglobinopathies
Q488-495: Disorders of Immune System
Q496-497: Inherited Abnormalities of Platelets
Q498-500: Inherited Disorders of Metabolism
Q501-505: Histocytic Disorders
Q506-509: Autoimmune Diseases
Q510-511: Tolerance Induction Associated with Solid Organ Transplant
Q512: Other Disease
2450: Post-TED
Q1-6: Survival
Q7-13: Subsequent Transplant
Q14-16: Initial ANC Recovery
Q17-18: Initial Platelet Recovery
Q19-44: Graft versus Host Disease (Allogeneic Only)
Q45-47: Liver Toxicity Prophylaxis
Q48-49: Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)
Q50-51: Infection
Q52-59: New Malignancy, Lymphoproliferative or Myeloproliferative Disorder
Q60-79: Chimerism Studies (Cord Blood Units, Beta Thalassemia, and Sickle Cell Disease Only)
Q80-102: Disease Assessment at the Time of Best Response to HCT
Q103-107: Post-HCT Therapy
Q108-118: Relapse or Progression Post-HCT
Q119-122: Current Disease Status
Comprehensive Baseline & Follow-up Manuals
2000: Recipient Baseline
Q1-3:Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning)
Q4-22: Organ Function Prior to the Preparative Regimen (Conditioning)
Q23-34: Hematologic Findings Prior to the Preparative Regimen (Conditioning)
Q35-38: Infection
Q39-85: Pre-HCT Preparative Regimen (Conditioning)
Q86-103: Additional Drugs Given in the Peri-Transplant Period
Q104-117: Socioeconomic Information
2004: Infectious Disease Markers
Q1: Donor/Cord Blood Unit Identification
Q2-29: Infectious Disease Markers
2005: Confirmation of HLA Typing
Q1: Donor/Cord Blood Unit Identification
Q2-24: HLA Typing by DNA Technology
Q25-30: Antigens Defined by DNA Technology
Q31-47: Optional Antigen Reporting
2006: Hematopoietic Stem Cell Transplant (HCT) Infusion
Q1-3: Pre-Collection Therapy
Q4-7: Product Collection
Q8-21: Product Transport and Receipt
Q22-40: Product Processing / Manipulation
Q41-93: Product Analysis (All Products)
Q94-143: Product Infusion
Q144-170: Donor/Infant Demographic Information
2100: Post-HCT Follow-Up
Q1-5: Vital Status
Q6-12: Granulopoiesis / Neutrophil Recovery
Q13-18: Megakaryopoiesis / Platelet Recovery
Q19-48: Growth Factor and Cytokine Therapy
Q49-63: Current Hematologic Findings
Q64-88: Immune Reconstitution
Q89-107: Chimerism Studies
Q108-130: Engraftment Syndrome
Q131-233: Acute Graft vs. Host Disease (GVHD)
Q234-406: Chronic Graft vs. Host Disease (GVHD)
Q407-427: Infection Prophylaxis
Q428-440: Infection
Q441-615: Organ Function
Q616-639: New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder
Q640-664: Functional Status
Q665-672: Subsequent HCT
2900: Recipient Death
Q1-4: Recipient Death Data
Cause of Death Codes
Comprehensive Disease-Specific Manuals
2010/2110: Acute Myelogenous Leukemia (AML)
AML Response Criteria
2010: AML Pre-Infusion
Q1-13: Disease Assessment at Diagnosis
Q14-31: Laboratory Studies at Diagnosis
Q32-68: Pre-HCT or Pre-Infusion Therapy
Q69-96: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
2110: AML Post-Infusion
Q1-40: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q41-50: Post-HCT / Post-Infusion Therapy
Q51-103: Disease Detection Since Date of Last Report
Q104-144: Disease Status at the Time of Evaluation for This Reporting Period
2011/2111: Acute Lymphoblastic Leukemia (ALL)
ALL Response Criteria
2011: ALL Pre-Infusion
Q1-19: Laboratory Studies at Diagnosis
Q20-63: Pre-HCT or Pre-Infusion Therapy
Q64-91: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
2111: ALL Post-Infusion
Q1-34: Disease Assessment at the Time of Best Response to HCT
Q35-47: Post-HCT / Post-Infusion Therapy
Q48-94: Disease Detection Since Date of Last Report
Q95-130: Disease Status at the Time of Evaluation for This Reporting Period
2012/2112: Chronic Myeloid Leukemia (CML)
CML Response Criteria
2012: CML Pre-Infusion Data
Q1-17: Disease Assessment at Diagnosis
Q18-83: Laboratory Studies at Diagnosis
Q84-185: Pre-HCT or Pre-Infusion Therapy
Q186-191: Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
Q192-252: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
Q253-256: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
2112: CML Post-Infusion Data
Q1-63: Disease Assessment at the Time of Best Response
Q64-99: Post-HCT / Post-Infusion Planned Therapy
Q100-109: Disease Relapse or Progression Post-HCT / Post-Infusion
Q110-194: Post-HCT / Post-Infusion Therapy
Q195-198: Disease Status at Time of Evaluation for this Reporting Period
2013/2113: Chronic Lymphocytic Leukemia (CLL)
CLL Response Criteria
2013: CLL Pre-Infusion
Q1-21: Disease Assessment at Diagnosis
Q22-73: Laboratory Studies at Diagnosis
Q74-148: Pre-HCT or Pre-Infusion Therapy
Q149-191: Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
Q192-193: Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
2113: CLL Post-Infusion
Q1-3: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q4-26: Disease Assessment at the Time of Best Response
Q27-42: Post-HCT / Post-Infusion Planned Therapy
Q43-88: Disease Relapse or Progression Post-HCT / Post-Infusion
Q89-113: Disease Status at the Time of Evaluation for This Reporting Period
2014/2114: Myelodysplastic Syndrome (MDS)
MDS Response Criteria
2014: Myelodyplastic Syndrome (MDS) Pre-Infusion
Q1: Subsequent Transplant of Cellular Therapy
Q2-17: Disease Assessment at Diagnosis
Q18-47: Diagnostic Studies (Measured Prior to First Disease Treatment)
Q48-81: IPSS-R Prognosis Score
Q82-156: Pre-HCT / Pre-Infusion Therapy
Q157-193: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
Q194-208: Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen
2114: Myelodysplastic Syndrome (MDS) Post-Infusion
Q1-72: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q73-87: Post-HCT / Post-Infusion Therapy
Q88-171: Most Recent Laboratory Studies
Q172-236: Disease Status at the Time of Evaluation for this Reporting Period
2015/2115: Juvenile Myelomonocytic Leukemia (JMML)
JMML Response Criteria
2015: JMML Pre-HCT
Q1-6: Clinical Features at Diagnosis
Q7-48: Laboratory Values at Diagnosis
Q49-62: Pre-HCT Therapy
Q63-64: Transformation
Q65-91: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen
Q92-93: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen
2115: JMML Post HCT
Q1-3: Disease Assessment at the Time of Best Response to HCT
Q4-10: Relapse or Progression Post-HCT
Q11-19: Post-HCT Therapy
Q21-22: Disease Status at the Time of Evaluation for this Reporting Period
2016/2116: Plasma Cell Disorders (PCD)
Multiple Myeloma Response Criteria
Plasma Cell Leukemia Response Criteria
POEMS Response Criteria
Amyloidosis Response Criteria
New York Heart Association Function Classifications
2016: PCD Pre-Infusion
Q1-2: Disease Assessment at Diagnosis
Q3-60: Diagnostic Studies (Measured Prior to Any Disease Treatment)
Q61-124: Amyloidosis Organ Involvement at Diagnosis
Q125-156: POEMS Syndrome Assessment at Diagnosis
Q157-187: Pre-HCT Therapy
Q188-255:Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen
Q256-290: Amyloidosis Organ Involvement at Last Evaluation Prior to the Start of the Preparative Regimen
Q291-296: POEMS Syndrome Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
2116: PCD Post-Infusion
Q1-2: Disease Specificity
Q3-53: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response
Q110-141: POEMS Syndrome Assessment at the Time of Best Response
Q142-210: Post-Infusion Therapy
Q211-252: Disease Status at the Time of Evaluation for this Reporting Period
Q253-311: Current Status of Amyloidosis for this Reporting Period
Q312 – 343: Current Status of POEMS Syndrome for This Reporting Period
2018/2118: Hodgkin and Non-Hodgkin Lymphoma
Lymphoma Response Criteria
2018: LYM Pre-Infusion
Q1-55: Disease Assessment at Diagnosis
Q56-68: Laboratory Studies at Diagnosis
Q69-81: Assessment of Nodal and Organ Involvement at Diagnosis
Q82-139: Disease Assessment at Transformation
Q140-152: Laboratory Studies at Transformation
Q153-165: Assessment of Nodal and Organ Involvement at Transformation
Q166-223: Pre-HCT Therapy
Q224-233: Disease Assessment at the Failure of the 1st Line of Therapy (DLBCL only)
Q234-288: Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
2118: LYM Post-Infusion
Q1-20: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q21-35: Post-HCT or Post-Infusion Therapy
Q36-86: Disease Relapse or Progression Since the Date of Last Report
Q87-90: Disease Status at the Time of Evaluation for this Reporting Period
2019/2119: Waldenström’s Macroglobulinemia (WM)
Waldenstrom’s Macroglobulinemia Response Criteria
2019: WM Pre-HCT
Q1-2: Disease Assessment at Diagnosis
Q3-23: Clinical Features Present at Diagnosis
Q24-75: Laboratory Studies at Diagnosis
Q76-120: Pre-HCT Therapy
Q121-150: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen
Q151-152: Disease Status at Last Evaluation Prior to the Preparative Regimen
2119: WM Post-HCT
Q1-17: Disease Assessment at the Time of Best Response to HCT
Q18-58: Post-HCT Therapy
Q59-77: Laboratory Studies at the Time of Evaluation for this Reporting Period
Q78-79: Disease Status at the Time of Evaluation for this Reporting Period
2026/2126: Neuroblastoma
Neuroblastoma Response Criteria
2026: Neuroblastoma Pre-Infusion
Q1 – 61: Clinical and Laboratory Characteristics at Diagnosis
Q62 – 232: Laboratory Values at Diagnosis of Neuroblastoma
Q233 – 271: Disease Status Immediately Prior to Preparative Regimen
2126: Neuroblastoma Post-Infusion
Q1 – 159: Disease Assessments at Time of Best Response to HSCT
2028/2128: Aplastic Anemia
2028: Aplastic Anemia Pre-Infusion
Q1: Subsequent Infusion
Q2-33: Disease Assessment
Q34-58: Laboratory Studies at Diagnosis
Q59-70: Pre-Infusion Therapy
Q71-77: Transfusion Status from Diagnosis to the Start of the Preparative Regimen / Infusion
Q78-95: Laboratory Findings Prior to the Start of the Preparative Regimen / Infusion
2128: Aplastic Anemia Post-HCT
Q1-25: Disease Assessment at the Time of Assessment for This Reporting Period
2029/2129: Fanconi Anemia / Constitutional Anemia
2029: Fanconi Anemia / Constitutional Anemia Pre-HCT
Q1 – 141: Disease Assessment at Diagnosis
Q142 – 176: Familial History of Disease
Q177: Clinical Features Just Prior to the Preparative Regimen
Q178 – 215: Hematologic Parameters Immediately Prior to the Preparative Regimen
2129: Fanconi Anemia / Constitutional Anemia Post-HCT
Q1 – 6: Current Hematologic Parameters
2030/2130: Sickle Cell Disease (SCD)
2030: SCD Pre-Infusion
Q1: Subsequent Transplant or Cellular Therapy
Q2-5: Disease Classification at Diagnosis
Q6-18: Transfusion Therapy
Q19-21: Iron Therapy
Q22-26: Pulmonary Assessments
Q27-37: Cardiovascular Assessments
Q38-46: Hepatic Assessments
Q47-51: Renal Assessments
Q52-56: Splenic Assessments
Q57-61: Acute Chest Syndrome
Q62-64: Pain
Q65-67: Avascular Necrosis
Q68-76: Central Nervous System
Q77-85: Other Symptoms
Q86-92: Disease Modifying Therapies
Q93-119: Other Laboratory Studies
Q120-121: Reason for Transplant
2130: SCD Post-Infusion
Q1-5: Physical Assessments
Q6-8: Transfusion Therapy
Q9-13: Pulmonary Assessments
Q14-30: Cardiovascular Assessments
Q31-37: Renal Assessments
Q38-42: Splenic Assessments
Q43: Acute Chest Syndrome
Q44-46: Pain
Q47-49: Avascular Necrosis
Q50-58: Central Nervous System
Q59-66: Other Symptoms
Q67-73: Disease Modifying Therapies
Q74-100: Other Laboratory Studies
Q101: Disease Status
2031/2131: Immune Deficiencies (ID)
2031: ID Pre-HCT
Q1-8: Disease Assessment at Diagnosis
Q9-50: Laboratory Studies at Diagnosis
Q51-115: Clinical Features Assessed Between Diagnosis and the Start of the Preparative Regimen
Q116-191: Pre-HCT Therapy for Immune Deficiency
2131: ID Post-HCT
Q1-43: Laboratory Studies Post-HCT
Q44-94: Clinical Features Assessed Post-HCT
Q95-166: Post-HCT Treatment for Immune Deficiency
Q167-172: Status of Hematologic Engraftment
2033/2133: Wiskott-Aldrich Syndome (WAS)
2033: WAS Pre-HCT
Q1-13: Disease Assessment at Diagnosis
Q14-41: Laboratory Studies at Diagnosis
Q42-130:Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen
2133: WAS Post-HCT
Q1-50: Laboratory Studies Post-HCT
Q51-105: Clinical Status of Recipient Post-HCT
Q106-167: Post-HCT Treatment for Wiskott-Aldrich Syndrome
Q169-174: Status of Hematologic Engraftment
2034/2134: X-Linked Lymphoproliferative Sydrome (XLP)
2034: XLP Pre-HCT
Q1-23: Disease Assessment at Diagnosis
Q24-32: History of Epstein Barr Virus (EBV) Infection
Q33-51: Assessment of Immunologic Function at Diagnosis
Q52-104: Disease Assessment between Diagnosis and the Start of the Preparative Regimen
Q105-130: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen
2134: XLP Post-HCT
Q1-19: Disease Assessment Since the Date of Last Report
Q20-30: Current Assessment of Immunologic Fuction Post-HCT
Q31-41: Laboratory Studies at the Time of Evaluation for This Reporting Period
2039/2139: Hemophagocytic Lymphohistiocytosis (HLH)
2039: HLH Pre-HCT
Q1-22: Disease Assessment at Diagnosis
Q23-47: Clinical Features and Laboratory Studies at Diagnosis
Q48-58: Disease Assessment Between Diagnosis and the Start of the Preparative Regimen
Q59-74: History of Infection at Any Time Prior to the Preparative Regimen
Q75-107: Pre-HCT Therapy
Q108-127: Clinical Features and Laboratory Studies At Last Evaluation Prior to the Start of the Preparative Regimen
2139: HLH Post-HCT
Q1-32: Disease Assessment Since the Date of Last Report
2057/2157 Myeloproliferative Neoplasms (MPN)
MPN Response Criteria
2057: Myeloproliferative Neoplasm (MPN) Pre-Infusion
Q1: Subsequent Transplant
Q2-10: Disease Assessment at Diagnosis
Q11-40: Diagnostic Studies (Measured Prior to First Disease Treatment)
Q41-54: DIPSS Prognosis Score
Q55-212: Pre-HCT / Pre-Infusion Therapy
Q213-254: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion
Q255-261: Disease Assessment at the Last Evaluation Prior to the Preparative Regimen / Infusion
2157: Myeloproliferative Neoplasm (MPN) Post-Infusion
Q1-86: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q87-104: Post-HCT / Post-Infusion Therapy
Q105-202: Disease Detection Since the Date of Last Report
Q203-287: Disease Status at the Time of Evaluation for this Reporting Period
Cellular Therapy Manuals
3500: Subsequent Neoplasms
Q1-23: New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder
3501: Pregnancy Form
Q1-6: Functional Status
4000: Cellular Therapy Essential Data Pre-Infusion
Q1-17: Recipient Data
Q18-32: Cellular Therapy and HCT History
Q33-57: Product Identification
Q58-77: Indication for Cellular Therapy
Q78-84: Lymphodepleting Therapy Prior to Cellular Therapy
Q85-88: Toxicity Prophylaxis
Q89-99: Hematologic Findings Prior to Lymphodepleting Therapy
Q100-102: Functional Status
Q103-113: Comorbid Conditions
4003: Cellular Therapy Product
Q1-2: Cellular Therapy Product Identification
Q3-12: Cell Product Source
Q13-15: Collection Procedure
Q16-37: Cell Product Manipulation
Q38-46: Cell Product Analysis
Q47: Product Infusion
4006: Cellular Therapy Infusion
Q1-31: Product Identification
Q32-35: Concomitant Therapy
4100: Cellular Therapy Essential Data Follow-Up
Q1: Product
Q2-3: Survival
Q4-8: Subsequent Cellular Infusions
Q9-11: Best Response to Cellular Therapy
Q12-20: Peripheral Blood Count Recovery
Q21-22: Disease Relapse or Progression
Q23-33: Current Hematologic Findings
Q34: New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder
Q35-59: Persistence of Cells
Q60-79: Graft vs. Host Disease
Q80-170: Toxicities
Q171-175: Infection
Q176-177: Pregnancy Status
Infection & Miscellaneous Manuals
2046 / 2146: Fungal Infection
2046: Fungal Infection Pre-Infusion Data
Q1-25: Infection Episode
Q26-31: Treatment of Infection
2146: Fungal Infection Post-Infusion Data
Q1-25: Infection Episode
Q26-42: Hematologic Findings at Diagnosis of Infection
Q43-49: Treatment of Infection
2047 / 2147: Hepatitis Serology
2047: Hepatitis Serology Pre-HCT
Q1-6: Serological Evidence of Prior Hepatitis Exposure / Infection – Recipient
Q7-26: History of Antiviral Therapy for Hepatitis – Recipient
Q27-34: Serological Evidence of Prior Hepatitis Exposure / Infection – Donor
Q35-54: History of Antiviral Therapy for Hepatitis – Donor
2147: Hepatitis Serology Post-HCT
Q1-9: Serological Evidence of Hepatitis Exposure / Infection – Recipient
Q10-17: Serological Evidence of Hepatitis Exposure / Infection – Donor
Q18-37: Antiviral Therapy for Hepatitis
2149: Respiratory Virus Post-Infusion Data
Q1-10: Infection Diagnosis
Q11-24: Hematologic Findings at Diagnosis of Infection
Q25-41: Therapy
2150: Viral Infection Diagnosis and Treatment Form
Q1-31: Infection Episode
Q32-50: Hematologic Findings at Diagnosis of Infection
Q51-76: Therapy
Q77: Infection Status at the Time of Evaluation for this Reporting Period
2540: Tepadina® Supplemental Data
Q1-2: Tepadina® Stop Date
Q3-35: Hematologic Findings
Q36-82: Organ Function
Q83-88: Data from Post-HSCT Follow-Up Form (2100)
2541: Inotuzumab Ozogamacin (Besponsa™) Supplemental Data
Q1-17: Inotuzumab Ozogamicin (Besponsa™)
2542: Mogamulizumab Supplemental Data Collection
Q1-3: Complications of Interest
Q4-9: Post-Infusion Critical Illness
2543: Mylotarg™ Supplemental Data Collection
Gemtuzumab ozogamicin (Mylotarg™) Administration Pre – HCT / Pre-Infusion
2553: VOD/SOS
Q1-28: Diagnosis
Q29-42: Laboratory Studies at Diagnosis
Q43-98: Therapy
Q99-112: Maximum Severity
Q113-145: VOD / SOS Status
Q146-153: Management of Late Sequelae
Q154-163: Hospital Stay
2565: Sanofi Mozobil Supplemental Data
Q1-3: Mobilization
Q4-56: Pre-Collection Therapy Given to Enhance Product Collection
Q57-74 Mobilization Agents
Q75-100: Apheresis Collection
Appendices
Appendix A: Abbreviations and Definitions
Appendix B: Glossary of Terms
Appendix C: Cytogenetic Assessments
Appendix D: How to Distinguish Infusion Types
Appendix E: Definition of a Product
Appendix F: Response Evaluation Criteria in Solid Tumors (RECIST)
Appendix G: Tracking Disease Status for Multiple Myeloma
Appendix H: MDS/MPN Subtypes
Appendix I: Ethnicity and Race
Appendix J: Reporting Comorbidities
Appendix K: Key Fields
Appendix L: Karnofsky/Lansky Performance Status
Appendix M: HCT Critical Data Fields
Appendix N: Drug Classification
Appendix O: Cellular Therapy Critical Fields
Download as PDF
Manual Reference Diagram
Click to enlarge
Last modified:
Mar 19, 2015
Getting Started
Providing Feedback
Need more help with this?
Don’t hesitate to contact us here.
Was this helpful?
Yes
No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
×
Thanks for your feedback.